Oculus Innovative Sciences Announces Fiscal Fourth Quarter Financial Results and Corporate Update Release and Conference Call

Download as PDF

Management to Update Market on Microcyn(R) Hydrogel Initiative, Additional New Products, Partner Expansion of Vetericyn(TM) Sales Effort in U.S., Activity Related to Swine Flu and Revenue Growth Targeting Profitability

PETALUMA, Calif.--(BUSINESS WIRE)-- Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, today announced that the financial results for its fiscal fourth quarter ended March 31, 2009, will be released after the U.S. market closes on June 11, 2009. The earnings release will be followed by a conference call at 1:30 p.m. PDT (4:30 p.m. ET) on June 11, 2009, to discuss fiscal fourth quarter results and provide a corporate update to the investment community.

Individuals interested in participating in the conference call may do so by dialing 877-397-0292 for domestic callers or 719-325-4907 for international callers. Those interested in listening to the conference call live via the Internet may do so at http://ir.oculusis.com/events.cfm. Please log on approximately 30 minutes prior to the presentation in order to register and download the appropriate software.

A telephone replay will be available for 48 hours following the conclusion of the call by dialing (888) 203-1112 for domestic callers, or (719) 457-0820 for international callers, and entering reservation code 2591974. A webcast replay will be available on the site at http://ir.oculusis.com/events.cfm for one year following the call.

About Oculus

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which includes new formulations designed to significantly reduce the need for antibiotics as it reduces infections. The Microcyn Technology platform features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increase blood flow to the wound site, and reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America. More information can be found at www.oculusis.com.

Oculus Innovative Sciences, Vetericyn, Microcyn and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners. 


    Source: Oculus Innovative Sciences, Inc.

Released May 28, 2009